Sana Biotechnology
SANA
132 hedge funds and large institutions have $511M invested in Sana Biotechnology in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 31 reducing their positions, and 27 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 31
4% more capital invested
Capital invested by funds: $493M → $511M (+$17.6M)
1.21% less ownership
Funds ownership: 64.75% → 63.54% (-1.2%)
3% less funds holding
Funds holding: 136 → 132 (-4)
15% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 27
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
84% less call options, than puts
Call options by funds: $303K | Put options by funds: $1.94M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.79M |
| 3 |
Morgan Stanley
New York
|
+$3.22M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$2.35M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.6M |
| 2 |
Public Sector Pension Investment Board (PSP Investments)
Montreal,
Quebec, Canada
|
-$6.33M |
| 3 |
SCM
Suvretta Capital Management
New York
|
-$5M |
| 4 |
CC
Casdin Capital
New York
|
-$2.9M |
| 5 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
-$2.66M |
SANA Hedge Fund Activity: Q4 2023 in Review
132 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q4 2023, worth a combined $511M — up 3.6% from $493M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of SANA and 23 opened new positions — a net loss of 4 holders — while 31 trimmed existing stakes and 51 added.
The largest buyer was Millennium Management, adding an estimated $6.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.6M.
- 132 institutional investors held Sana Biotechnology (SANA) as of Q4 2023, down from 136 in Q3 2023.
- Funds reported $511M of Sana Biotechnology stock for Q4 2023, up 3.6% quarter-over-quarter.
- 23 funds opened new Sana Biotechnology positions in Q4 2023 and 27 closed out, a net change of -4 holders.
- The largest Sana Biotechnology buyer in Q4 2023 was Millennium Management, an estimated $6.2M added.
- The largest Sana Biotechnology seller in Q4 2023 was T. Rowe Price Associates, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2023.